Radiopharmaceutical Market Scenario 2035

Report Details:

15 Companies Covered

200 Pages

Request Free Sample

Rising Demand for Targeted Therapies will Positively Impact the Global Radiopharmaceuticals Market at a CAGR of 9.12% during the Forecast Period 2025 to 2035

Market Research Future (MRFR) has published a cooked research report on the “Global Radiopharmaceuticals Market” that contains information from 2025 to 2035. The Radiopharmaceuticals Market is estimated to register a CAGR of 9.12% during the forecast period of 2025 to 2035.

MRFR recognizes the following companies as the key players in the Global Radiopharmaceuticals Market— Cardinal Health (US), GE Healthcare (GB), Bayer AG (DE), Novartis AG (CH), Siemens Healthineers (DE), Elekta AB (SE), Lantheus Medical Imaging (US), Bracco Imaging S.p.A. (IT), and NorthStar Medical Radioisotopes, LLC (US).

Radiopharmaceuticals Market Highlights

The Global Radiopharmaceuticals Market is accounted for to register a CAGR of 9.12% during the forecast period and is estimated to reach USD 18.52 Billion by 2035.

The growth of the market is primarily driven by technological advancements in nuclear medicine, increasing demand for personalized and targeted therapies, and a rising incidence of cancer worldwide. Radiopharmaceuticals are increasingly used for both diagnostic and therapeutic purposes, particularly in oncology and cardiology.

Significant progress in artificial intelligence (AI) and radiochemistry has enhanced the precision and safety of nuclear imaging and therapy. The growing adoption of personalized medicine has also accelerated demand for tailored radiopharmaceutical solutions, enabling patient-specific treatment approaches.

Furthermore, supportive regulatory frameworks across major regions, including the U.S. FDA and European Medicines Agency (EMA), are streamlining approval pathways and encouraging innovation. The market is expected to see major investments in automated radiopharmaceutical production facilities and novel radiotracers for neurodegenerative diseases in the coming years.

Segment Analysis

The Global Radiopharmaceuticals Market has been segmented based on Type, Application, End Use, and Radiopharmaceutical Class.

The Type segment is bifurcated into Diagnostic Radiopharmaceuticals (largest) and Therapeutic Radiopharmaceuticals (fastest-growing). Diagnostic Radiopharmaceuticals applications currently dominate due to widespread use in imaging modalities like PET and SPECT, while therapeutic applications are expanding rapidly with a growing focus on oncology and targeted therapies.

The Application segment is bifurcated into Diagnosis, Therapy, and Research. The Diagnosis segment holds the largest share, driven by increased adoption in cancer and cardiovascular disease imaging. The Therapy segment, however, is expected to exhibit the highest growth due to advancements in radiotherapeutics and personalized medicine.

The Radiopharmaceutical Class segment is bifurcated into Radioisotopes (dominant) and Radiolabeled Compounds (emerging). Radioisotopes remain essential for both diagnostic and therapeutic purposes, while radiolabeled compounds are gaining traction in targeted therapy.

The End Use segment is bifurcated into Hospitals (largest), Diagnostic Imaging Centers (fastest-growing), and Research Institutions (emerging). Hospitals dominate due to extensive infrastructure for administering radiopharmaceuticals, while diagnostic imaging centers are expanding with the rise of outpatient diagnostic facilities.

Region Analysis

By Region, the Radiopharmaceuticals Market is segmented into North America, Europe, Asia-Pacific, and the Middle East & Africa. North America dominates the global market, accounting for around 45% of the total share. The region benefits from advanced healthcare infrastructure, a high prevalence of cancer, and supportive regulatory frameworks. The U.S. leads the market, with strong contributions from Cardinal Health, GE Healthcare, and Lantheus Medical Imaging.

Key Findings of the Study

The Global Radiopharmaceuticals Market is expected to reach USD 18.52 Billion by 2035, at a CAGR of 9.12% during the forecast period.

North America accounted for the largest market share, while the Asia-Pacific is the fastest-growing region.

Based on Type, the Diagnostic Radiopharmaceuticals segment held the largest market in 2024.

Based on End Use, the Hospitals segment dominated the market in 2024.

Cardinal Health, GE Healthcare, Bayer AG, Novartis AG, Siemens Healthineers, Elekta AB, Lantheus Medical Imaging, Bracco Imaging S.p.A., and NorthStar Medical Radioisotopes, LLC are the key market players.